Recent Generic Drug Approvals Safe and Safe a



ach year, FDA approves scores of generic drugs that treat a variety of conditions and help consumers save money.

Generic drugs cost about 20% to 70% less than their brand name counterparts. The Congressional Budget Office has reported that generic drugs save consumers an estimated \$8 billion to \$10 billion a year.

Generic drugs are identical to their brandname equivalents in dosage, safety, strength, quality, performance characteristics, intended use, and the way they're administered to patients.

Drug manufacturers develop their new drugs under patents that protect their firms' investments in the products. When patents or other periods of exclusivity on the drugs expire, manufacturers can apply to FDA to sell generic versions.

In October 2007, FDA launched the Generic Initiative for Value and Efficiency (GIVE) to help increase the number of approvals of generic products.

GIVE will use existing resources to help FDA modernize and streamline the generic drug approval process. GIVE will also increase the variety of generic drug products available. 🗫

For More Information

FDA's GIVE Initiative www.fda.gov/oc/initiatives/advance/generics.html

FDA's Office of Generic Drugs www.fda.gov/cder/ogd/

Generic Drug Approvals (by month) www.fda.gov/cder/ogd/approvals/default.htm Significant approvals granted by FDA's Office of Generic Drugs during the past year include

• Alendronate Sodium Tablets

Used for: Treating and preventing types of osteoporosis Originally marketed as: Fosamax, by Merck & Co. Date approved: Feb. 6, 2008

• Carvedilol Tablets

Used for: Treating hypertension and heart failure Originally marketed as: Coreg, by SmithKline Beecham, now GlaxoSmithKline Date approved: Sept. 5, 2007

• Cetirizine HCl Tablets

Used for: Treating symptoms of allergies Originally marketed as: Zyrtec, by Pfizer Date approved: Dec. 12, 2007

• Granisetron Tablets

Used for: Preventing nausea and vomiting related to chemotherapy and radiation Originally marketed as: Kytril, by Roche Date approved: Dec. 31, 2007

• Oxcarbazepine Tablets

Used for: Treating certain kinds of seizures and epilepsy Originally marketed as: Trileptal, by Novartis Date approved: Oct. 9, 2007

• Pravastatin Sodium Tablets

Used for: Treating elevated cholesterol and preventing coronary events Originally marketed as: Pravachol, by Bristol-Myers Squibb

Date approved: Apr. 23, 2007

• Zolpidem Tartrate Tablets

Used for: Treating insomnia

Originally marketed as: Ambien, by Sanofi Aventis

Date approved: Apr. 23, 2007